Search

Objectives In some patients with systemic sclerosis (SSc), esophageal symptoms can be severe enough to warrant surgical intervention; however, no single procedure seems to predominate because there exists no published rationale for the choice of a particular procedure. We did a systematic literature review of all published trials involving patients with SSc requiring esophageal surgery and compared their relative outcomes and complications. Methods All articles (excluding review articles) describing esophageal surgeries in SSc patients published between 1965 and November 2015 were reviewed. A minimum of 12 weeks’ follow-up was also needed for inclusion. Primary outcome measures were improvement of patient- and/or physician-described reduction in heartburn, reflux or dysphagia. Complications related and unrelated to the procedure were also evaluated. Results Ten articles satisfied selection criteria. A total of 119 patients, all ≥18 years of age, were included from the 10 articles selected Excluding the 1-2 patient case reports, favorable responses were seen in 30%-81% of patients. Complications were varied and differed from series to series Conclusions The efficacy of the procedure and the specific surgical approach to use remains based on anecdotal data. There is clearly a need for careful, controlled studies in uniform groups of SSc patients before being able to rationally recommend esophageal surgery for dysphagia/heartburn in SSc.

Esophageal cancer is an extremely lethal human disease. Relatively little is known about the molecular mechanisms leading to esophageal cancers, nor the signaling pathways activated to maintain and augment the tumor growth. Esophageal cancer cell lines were evaluated to assess the effect of phorbol 12,13 dibutyrate on protein kinase C activity, indirectly using protein kinase D (formerly known as protein kinase C-μ), Akt activity, and cell proliferation. Treatment of esophageal cancer cell lines with the phorbol ester phorbol 12,13 dibutyrate led to a rapid and dramatic increase in the activation of protein kinase D. In addition, administration of phorbol 12,13 dibutyrate also decreased the phosphorylation of Akt. Interestingly, in the OE19 esophageal adenocarcinoma cell line, treatment with phorbol 12,13 dibutyrate also led to inhibition of cell growth. All the phorbol ester effects observed were reversible by combined treatment with a protein kinase C inhibitor, implicating protein kinase C in the cells' response to the phorbol ester. Overall, these studies suggest that protein kinase D (e.g. protein kinase C-μ) may behave as a tumor suppressor in some esophageal cancer samples, serving to inhibit Akt activity and block cell growth.

The objective of this study was to evaluate the capacity of three clinically useful tissue sources: tricuspid valve leaflet (TVL), carotid artery (CA), and jugular vein (JV), to generate myofibroblasts for potential use in a tissue-engineered cardiac valve replacement. Tissue biopsies of clinically appropriate sizes obtained from juvenile sheep were used for this work. Cells obtained from all three tissue sources exhibited a myofibroblast phenotype in vitro, as demonstrated by their immunoreactivity with antibodies directed against vimentin, alpha-smooth muscle actin, fibronectin, and chondroitin sulfate. Protein synthesis characteristics were defined for the key extracellular matrix components: collagen, glycosaminoglycans, and elastin. Among the three sources, JV generated the highest numbers of cells, and JV cells produced the largest amount of collagen per cell. These data suggest that venous tissue, with its relative ease of accessibility, may generate myofibroblasts potentially useful for the interstitial cellular component of a tissue-engineered cardiac valve.

Background Endoscopic ablation and vagal-sparing esophagectomy offer the potential for reduced morbidity in patients with high-grade dysplasia or early esophageal adenocarcinoma, but neither includes a lymphadenectomy. Although adequate for intramucosal tumors, both are potentially inadequate for patients with submucosal tumor invasion given the high prevalence of nodal metastases with these lesions. Currently there is no test including endoscopic ultrasound that can accurately determine whether a small tumor is confined to the mucosa or has penetrated into the submucosa. The aim of this study was to compare the pathologic depth of invasion by endoscopic mucosal resection with findings and outcome after surgical resection to assess the accuracy and reliability of endoscopic mucosal resection for staging early esophageal adenocarcinoma. Methods From 2001 to 2003, 7 patients presented with small, endoscopically visible adenocarcinomas. All underwent endoscopic mucosal resection followed by surgical resection. Results Analysis of the resected specimens confirmed that the endoscopic mucosal resection had accurately determined the depth of tumor invasion in all patients, and had completely excised the lesion in all but 1 patient (86%). Lymph node dissection was included as part of the resection in 2 patients with submucosal invasion by endoscopic mucosal resection, and a vagal-sparing esophagectomy was used in the 5 patients with only intramucosal tumors. All patients are alive and disease-free at a median follow-up of 7 months. Conclusions Endoscopic mucosal resection accurately determines the depth of tumor invasion, and should be used as a staging procedure in patients with early esophageal cancer when therapies that do not include a lymphadenectomy are considered.

This article discusses the diaphragm from a surgical perspective. Although it is a relatively simple organ compared with other structures, the diaphragm serves important anatomic and functional roles necessary for proper respiratory function. It is an organ of little irregularity or disease, and easily manipulated in the operating room by those who have a basic understanding of its anatomic details.

Background VATS has become a preferred method for benign surgical conditions, yet still remains controversial for malignancies. The purpose of this study was to review our results of pulmonary metastasectomies using both conventional open thoracotomy and VATS techniques. Methods This is a retrospective chart review of pulmonary metastasectomies performed from 1986 to 2006. The surgical approach used for the initial pulmonary metastasectomy was either open thoracotomy or VATS. Main outcomes were overall survival and recurrence free survival, evaluated using Kaplan Meier analysis. A non-inferiority margin was set at 0.2. Results A total of 280 surgical procedures were performed on 186 patients. From 171 eligible individuals, 135 patients were treated with thoracotomy (82 M, 53 F; median age 49 years), and 36 with VATS (18 M, 18 F; median age 58.5 years). Primary cancers were mainly: 81 sarcoma (47%), 26 colorectal adenocarcinoma (15%) and 22 renal cell carcinoma (13%). Median postoperative follow was 26.2 months. The conversion rate was 10.3% and there were no cases of pleural cavity seeding. The 5-year overall survival rates were 58.8% for thoracotomy and 69.6% for VATS, with median overall survival of 53.2 months and 30.1 months, respectively (p = 0.03). The estimated difference in 5-year overall survival was 10.8%. Second occurrences were noted in 59 thoracotomy and 10 VATS patients. The 5-year recurrence free survival rates were 51% in thoracotomy and 67% in VATS (p = 0.27), with median recurrence free survival of 24.8 months and 25.6 months, respectively. Conclusion In cases of pulmonary metastases, VATS is an acceptable alternative that is both safe and efficacious. Non-inferiority analysis of 5-year overall survival demonstrates that VATS is equivalent to thoracotomy. VATS patients also have a longer recurrence free survival. Based on our experience, it is permissible to use VATS resection in these circumstances: small tumor, fewer nodules, single lesion, age ≤ 53, unilateral, tumor size amenable to wedge resection, and non-recurrent disease.

Background Adenocarcinomas commonly metastasize to the lungs and can be resected using open thoracotomy or video-assisted thoracic surgery (VATS). This study reviews metastatic resections in primary adenocarcinoma patients, using both thoracotomy and VATS. We aim to compare long-term prognoses to test the efficacy and viability of VATS. Methods A retrospective review of primary adenocarcinoma patients who underwent resection of pulmonary metastases from 1990 to 2006 was carried out. Information was obtained by chart review. Endpoints analyzed were disease-free interval (DFI), survival time, and recurrence-free survival (RFS). Results In a total of 42 (16 male, 26 female; median age 58.5 years) primary adenocarcinoma patients, 21 patients underwent first pulmonary metastatic resection using VATS (7 male, 14 female; median age 57 years) and 21 using thoracotomy (9 male, 12 female; median age 59 years). Primary adenocarcinomas were mainly 27 colorectal (64%) and 11 breast (26%). Two VATS (10%) and three open patients (14%) had local recurrences of the original cancer. Median postoperative follow was 13.3 months [interquartile range (IQR) 4.5–32.8 months] for VATS and 36.9 months (IQR 19.3–48.6 months) after thoracotomy. Median DFI–1 was 22.3 months (IQR 13.5–40.6 months) for VATS patients and 35.6 months (IQR 26.7–61.3 months) for open patients. Second thoracic occurrences were noted in six VATS patients (median DFI–2 9.2 months), and in seven open patients (median DFI-2 21.5 months). Third thoracic occurrences were noted in one VATS patient (DFI-3 18.7 months) and in one thoracotomy patient (DFI-3 21.8 months). Odds ratio of recurrence showed 12.5% less chance of developing recurrence in VATS patients. Five-year RFS was 53% in VATS and 57% in thoracotomy patients. Conclusions VATS has become a viable alternative to open thoracotomy for resection of pulmonary metastases. In cases of primary adenocarcinoma, VATS showed no increase in number of thoracic recurrences, and comparable RFS. Short-term follow-up is encouraging; long-term follow-up will be needed to confirm these results.

Esophageal reconstruction is often the most challenging component of an esophagectomy, and is certainly the aspect most noted and evaluated by the patient. Unfortunately, there is no replacement organ that is able to mimic the function of a healthy esophagus. Instead, all suffer from a lack of effective peristalsis and the absence of a physiologic barrier to reflux. Despite these shortcomings, available esophageal replacement organs permit most patients to eat very satisfactorily, and in patients who undergo esophagectomy for large tumors or severe strictures, swallowing is often significantly improved. The most common esophageal substitute is the stomach. Advantages of a gastric pull-up include the relative speed and ease with which the stomach can be mobilized, the need for only one anastomosis, and the generally reliable blood supply through the right gastroepiploic arcade along the greater curvature. Disadvantages of a gastric pull-up include the fact that there is often relative ischemia at the tip of the fundus, and the leak and stricture rate of a cervical esophago-gastric anastomosis can be as high as 30%. In addition, the long-term presence of acid-secreting gastric mucosa juxtaposed to acidsensitive squamous esophageal mucosa with no intervening barrier can lead to complications of reflux, including Barrett’s esophagus and adenocarcinoma [1]. Finally, in patients who have large tumors near the gastroesophageal junction, use of the stomach may compromise the oncologic resection, because the gastric staple line along the lesser curve is likely to be within a few centimeters of the neoplasm.

As progress is made in the development of a tissue-engineered cardiac valve, the need for a reliable cell source is particularly important. A technique has been developed for the reliable biopsy of tricuspid valve leaflets. Expanding the harvested cells in culture is feasible and provides a source of leaflet cells that are structurally and functionally similar to the pulmonary and aortic valve leaflet cells that they may replace.Thirteen sheep underwent tricuspid valve biopsy. Transthoracic echocardiography (TTE) was performed to evaluate function and guide the subsequent biopsy. Myofibroblasts were isolated from the biopsy samples, expanded in culture through 10 passages, and evaluated with immunocytochemistry for valve cell markers. Two animals were sacrificed acutely, two animals died during the immediate postoperative period, and nine animals survived for four weeks or more.All preoperative and pre-explantation echocardiograms were normal. Both animals sacrificed acutely showed that the tricuspid valve leaflet was indeed biopsied with this technique. Two perioperative deaths occurred; one animal died secondary to injury of the chorda tendinea with subsequent destruction of the posterior leaflet; another died from disruption of the superior vena cava that led to irreversible cardiac tamponade. At sacrifice (2 to 17 weeks), all other animals showed intact tricuspid valves with normal leaflet anatomy. All cultured biopsies generated myofibroblasts that were immunocytochemically positive for alpha smooth muscle actin, chondroitin sulfate, vimentin and fibronectin.Biopsy of the tricuspid valve to obtain recipient cardiac valve leaflet cells is possible, and the technique is simple and reliable. Biopsy of the leaflet does not compromise function. Interstitial cells can be harvested and expanded in culture. Cellular structure and function is preserved and is similar to that of other cardiac leaflet cells. Tricuspid valve leaflet biopsies are a potential source for harvesting cells to be used in the development of a tissue-engineered cardiac valve.

Introduction The surgical management and clinical outcome of esophageal cancer continue to improve with advances in surgical techniques and better perioperative care. We reviewed our experience with esophagectomies for esophageal cancer from 1970-2005. Trends in surgical outcomes and specific postoperative morbidities were evaluated over this 35-year period. Methods A retrospective study was conducted of the hospital records of all patients who underwent esophagectomies for esophageal cancer (including the gastroesophageal junction) at the University of California Los Angeles Medical Center between January 1, 1970 and September 1, 2005. Three groups of patients were evaluated: remote, past and present: operated between 1970 and 1983 (n = 111), 1984 and 1993 (n = 205), and 1994 and present (n = 151), respectively. Our main perioperative outcome measures were operative mortality, cardiac arrhythmia, renal failure, pulmonary complication, anastomotic leaks, and reoperations. Results There were 467 patients, 354 male, 113 female. Two hundred forty-seven underwent transthoracic esophagectomy and 177 underwent transhiatal esophagectomy, 9 underwent a transabdominal resection, 18 underwent palliative bypass surgery, and 16 had an open and close surgery. Four hundred thirty-two had an esophagectomy with a gastric pull-up and two had colon interpositions. Six were done laparoscopically and two were robot-assisted. When the remote, past, and present groups were compared, we noted the following: operative mortality was 10%, 3%, 4%, respectively; the rate of re-operation was 20%, 8%, 9%, respectively; anastomotic leaks were noted in 12%, 5%, and 2% of patients, respectively; pulmonary complications were noted in 50%, 34%,19% of patients, respectively; cardiac complications were noted in 31%, 18%, 15% of patients, respectively; and renal complications were noted in 6%, 2%, 3%, respectively. Conclusions Surgical outcomes of patients undergoing an esophagectomy for cancer have changed over the past 35 years. Significant improvements have been made with respect to pulmonary complications and anastomotic leaks. Further studies need to be done to determine the factors that have contributed to the trends observed in this study.